Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants

Leukemia

Volumn 16, Issue 6, 2002, Pages 1160-1166

  Janowska Wieczorek, A ^c,d   Majka, M ^a   Marquez Curtis, L ^d   Wertheim, J A ^b   Turner, A R ^c   Ratajczak, M Z ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d CANADIAN BLOOD SERVICES   (Canada)

Author keywords

Angiogenesis; Bcr abl constructs; Chronic myelogenous leukemia; Matrix metalloproteinases; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; BCR ABL PROTEIN; CD34 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; GROWTH FACTOR; HEMOGLOBIN; INTERLEUKIN 8; MATRIGEL; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; PROTEIN P185; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL ISOLATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM; FEMALE; GENE TRANSLOCATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMOGENESIS; MALE; MONONUCLEAR CELL; MOUSE; MYELOBLAST; NONHUMAN; PRIORITY JOURNAL; VASCULARIZATION; WILD TYPE;

EID: 85014301696     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402486     Document Type: Article

References (46)

1. How is blood vessel growth regulated in normal and neoplastic tissue?
2. Blood vessel formation: What is its molecular basis?
3. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
4. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia
5. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells
6. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
7. Angiogenic factors in multiple myeloma: Higher levels in bone marrow than in peripheral blood
8. Angiogenesis in myelodysplastic syndromes
9. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
10. Regulation of hematopoiesis by microvascular endothelium
11. The thin red line: Angiogenesis in normal and malignant hematopoiesis
12. Role of vascular endothelial growth factor (VEGF), placenta derived growth factor (PIGF)/Flt-1 and Flk-1/KDR receptor axes in human adult and fetal hematopoiesis
13. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity
14. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention
15. Matrix metalloproteinases and tumor invasion: From correlation and causality to the clinic
16. + cells and their transmigration through reconstituted basement membrane
17. Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: Comparison with normal bone marrow cells
18. Unstimulated human acute myelogenous leukemia blasts secrete matrix metalloproteinases
19. Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas
20. Matrix metalloproteinase and tissue inhibitors of metalloproteinase secretion by haematopoietic and stromal precursors and their production in normal and leukaemic long-term marrow cultures
21. The molecular biology of chronic myeloid leukemia
22. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL
23. The biology of chronic myeloid leukemia
24. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype
25. Enrichment of hematopoietic precursor cells and cloning of multipotential B-lymphocyte precursors
26. Transduction of genes using retrovirus vectors
27. Analysis of the biologic properties of p230 bcr-abl reveals unique and overlapping properties with the oncogenic p185 and p210 bcr-abl tyrosine kinases
28. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow
29. + cells, myeloblasts, erythroblasts and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner
30. Stromal derived factor-1 and thrombopoietin regulate distinct aspects of human megakaryopoiesis
31. + cells and megakaryoblasts secrete β-chemokines; implications for infectability by M-tropic human immunodeficiency virus (R5 HIV)
32. + cells in response to chemokines
33. Monitoring mRNA expression by polymerase chain reaction: The 'primer-dropping' method
34. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis
35. Tumor cell responses to IFNγ affect tumorigenicity and responses to IL-12 therapy and antiangiogenesis
36. Down-regulation of interleukin-3/granulocyte-macrophage colony stimulating factor receptor beta-chain in bcr-abl+ human leukemic cells: Association with loss of cytokine-mediated Stat-5 activation and bcr-abl inhibition
37. Tyrophostin AG957, a tyrosine kinase inhibitor with anti-bcr/abl tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors
38. Bcr-abl down-regulates the DNA repair protein DNA-PKcs
39. The p190, P210, and P230 forms of BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity
40. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro
41. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration
42. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
43. Examining the relationship between the gelatinolytic balance and the invasive capacity of endothelial cells
44. Tissue inhibitor of metalloproteinase-2 inhibits bFGF-induced human microvascular endothelial cell proliferation
45. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases
46. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes